Proinflammatory cytokines in irritable bowel syndrome: a comparison with inflammatory bowel disease

Antigony Mitselou; Vasileios Grammeniatis; Anna Varouktsi; Stamatis S Papadatos; Konstantinos Katsanos; Vasiliki Galani

doi:10.5217/ir.2019.00125

Articles

Page Path: HOME > Intest Res > Volume 18(1); 2020 > Article

Original Article Functional bowel disorder Proinflammatory cytokines in irritable bowel syndrome: a comparison with inflammatory bowel disease: Antigony Mitselou¹, Vasileios Grammeniatis², Anna Varouktsi³, Stamatis S Papadatos⁴, Konstantinos Katsanos⁵, Vasiliki Galani^6,; Intestinal Research 2020;18(1):115-120.
DOI: https://doi.org/10.5217/ir.2019.00125
Published online: January 30, 2020

¹Department of Forensic Pathology, Medical School University of Ioannina, Ioannina, Greece

²Department of Paediatrics, General Hospital of Ioannina, Ioannina, Greece

³Department of Internal Medicine, Ippokratio Hospital, Thessaloniki, Greece

⁴³rd Department of Internal Medicine, Sotiria General Hospital, National and Kapodistrian University of Athens Medical School, Athens, Greece

⁵Hepato-Gastroenterology Unit, 1st Department of Internal Medicine, Greece

⁶Department of Anatomy, Histology, and Embryology, Medical School University of Ioannina, Ioannina, Greece

Correspondence to Vasiliki Galani, Department of Anatomy, Histology, and Embryology, Medical School University of Ioannina, Dourouti, Ioannina 45110, Greece. Tel: +30-2651007587, Fax: +30-2651007860, E-mail: vgalani@uoi.gr

• Received: October 1, 2019 • Revised: November 12, 2019 • Accepted: December 3, 2019

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

prev next

7,687 Views
197 Download
34 Web of Science
34 Crossref
39 Scopus

Full Article

Download PDF

Abstract
INTRODUCTION
METHODS
RESULTS
DISCUSSION
NOTES
REFERENCES

Abstract

Background/Aims
Irritable bowel syndrome (IBS) is a common disease often considered as a functional intestinal disorder. Inflammation in IBS is a quite intriguing theory. The aim of this study was to investigate tumor necrosis factor (TNF)-α, interleukin (IL)-1β and IL-6 expression in inflammatory bowel disease (IBD) patients, IBS patients and normal controls.
Methods
IBS and IBD patients along with normal controls were recruited in the study. In all groups, 2 pinch biopsies were taken at each of 3 anatomical sites (terminal ileum, cecum, and rectum). IBS patients were also subcategorized according to the syndrome clinical manifestations. Two monoclonal antibodies (mAb), TNF-α mAb and IL-6 mAb, and one polyclonal antibody IL-1β mAb were applied for immunohistochemical analysis.
Results
In IBD patients intensity of TNF-α and IL-1β were lower than in IBS patients or controls, while IL-6 was significantly increased comparing to the aforementioned groups. In IBS patients TNF-α was increased comparing to IBD patients or controls, while IL-6 and IL-1β were similar to controls. In IBS subgroups, TNF-α was lower in diarrhea predominant IBS patients and higher constipation predominant IBS patients. Differences among IBS subgroups regarding IL-6 and IL-1β were nonsignificant.
Conclusions
IL-6 seems to be the most important proinflammatory cytokine in IBD patients, while TNF-α could play a more significant role in IBS pathogenesis.
Keywords: Proinflammatory cytokines; Irritable bowel syndrome; Inflammatory bowel disease

INTRODUCTION

Irritable bowel syndrome (IBS) is a chronic, fluctuating disorder with frequent relapses that affects approximately 20% of adults, accounts for 40% of referrals to gastroenterology clinics, and comprises 12% of general-practitioner consultations [1]. IBS is a disorder without a clear and uniform biochemical, anatomical or pathophysiological substrate. The most prominent symptoms are abdominal pain or abdominal discomfort and an altered defecation pattern. As there are, by definition, no biological parameters for diagnostic discretion in IBS, symptoms constitute a reliable basis for classification and diagnosis. Several acknowledged criteria such as “Manning criteria” followed by the “Kruis criteria” and the “Rome criteria (I-III),” have been used in order to establish diagnosis.

IBS has been considered a common functional disorder implying a disorder without a discernible pathophysiological mechanism, thus a nonorganic disorder [2,3]. Traditionally, IBS has been viewed upon as a disorder where altered GI motility, visceral hypersensitivity, dysregulation of brain-gut axis, altered bowel motility, neurotransmitter imbalances and psychosocial factors are the most important pathophysiological factors [4,5].

The lack of an orchestrator of the IBS mystery is probably the more significant quest regarding the disease. The last few years an emerging theory of inflammation as the key pathophysiological factor in IBS has become quite intruiging [1,6,7].

The aim of this study was to investigate mucosal levels of ΤNF-α, interleukin (IL)-6 and IL-1β in inflamed mucosa (IBD patients), in non-inflamed mucosa (normal controls) as well as in assumed non-inflamed mucosa of patients with IBS.

METHODS

1. Patients

IBS and IBD patients along with normal controls were recruited in the study. Characteristics of IBS and IBD patients and normal controls are described at Table 1. Data regarding IBD patients were mostly retrospective, while IBS patients and controls were recruited prospectively. All subjects underwent colonoscopy after cleansing of their whole colon with polyethylene glycol-electrolyte lavage solution. In all cases, 2 pinch biopsies were taken at each of the 3 anatomical sites (terminal ileum, cecum and rectum). IBD was diagnosed upon clinical end endoscopical criteria as well as by biopsy findings. The endoscopic classification for the IBD group was established using Mayo clinic index and UC endoscopic index for severity [8]. Biopsies obtained from IBD patients with colitis were used as inflammatory disease controls. IBD specimens include patients with CD (CD-terminal ileum), with UC (UC-rectum) and both CD and UC patients (cecum).

IBS patients fulfilled the Rome III criteria and none of them had a clear history of IBD. IBS patients were further subcategorized according to their bowel habits (IBS-D, diarrhea predominant IBS; IBS-C, constipation-predominant IBS; IBS-A, patients with alternating symptoms) in order to detect variations in the expression of TNF-α, IL-6, IL-1β in those subgroups. As normal controls were used patients that underwent colonoscopy for polypectomy or investigation of anemia or hematochezia or even patients with colon cancer that had a part of their colon surgically removed (bowel parts remote to cancer margins were used). Controls had: (1) macroscopically and histologically normal colonic mucosa; (2) no persistent bowel symptoms; (3) no organic or functional bowel disease; and (4) no history of chronic medical disease. None of IBD, IBS patients or normal control cases received any anti-inflammatory regimen prior to the time of biopsy.

2. Methods

Tissue specimens were formalin-fixed, embedded in paraffin cubes and 4-μm thick sections were obtained for immunohistochemical study. Immunohistochemical staining was performed on an automated immunostainer (Ventana Benchmark, Strasbourg, France), according to the manufacturer’s protocols.

Antibodies directed against ΤNF-α (dilution 1:100, clone P/T2; Abcam Inc, Cambridge, UK), IL-6 (dilution 1:100, clone 10C12; Leica Biosystems, Wetzlar, Germany) and IL-1β (Thermo Fisher Scientific Inc, Waltham, MA, USA) were applied. Finally, slides were washed in tap water, dehydrated, and mounted with glass coverslips. Positive controls were used to confirm the adequacy of the staining and negative controls were included and consisted in the same immunohistochemical method with omission of the primary antibody.

For the counting of immunopositive TNF-α, IL-6 and IL-1β cells a semiquantitative score system that considered staining intensity on epithelium and crypts was adopted by using the × 40 objective lens and counting at least 5 nonoverlapping fields selected on the basis they contained immunopositive cells. Intensity of TNF-α, IL-6 and IL-1β staining was evaluated as weak (+1), moderate (+2), intense (+3) or severe (+4) on a subjective basis. All immunohistochemical sections were evaluated by 2 independent experienced pathologists. The grade of inflammation was assessed under the same light microscope at × 40 magnification by the same pathologists.

Statistical analysis was performed with SPSS software. Kruskal-Wallis one-way ANOVA test was used to assess the statistical differences between the aforementioned groups. P< 0.05 indicated a statistically significant difference.

3. Ethical Considerations

This study was conducted according to the Ethical Guidelines for Medical and Health Research Involving Human Subjects. The present study was approved by the Ethics Review Committee of University of Ioannina (approval No. 515α/11-11-2003). No additional permissions were required to review the patient records, including the hospitals from which the records were obtained.

RESULTS

1. TNF-α

Intensity of TNF-α was lower in IBD patients through terminal ileum, cecum and rectum, compared to IBS patients and controls (P< 0.05) (Table 2). A nonsignificant increase of TNF-α intensity in IBS patients compared to controls was showed, except at cecum epithelium (P= 0.03).

2. IL-6

Intensity of IL-6 appeared higher in IBD patients compared to IBS patients and controls (IBD vs. IBS, P< 0.05) throughout the bowel (Table 2). When comparing expression of IL-6 in IBS patients and controls, no definite pattern was revealed.

3. IL-1β

Intensity of IL-1β was lower in IBD patients compared to IBS patients and controls (IBD vs. controls, P< 0.05; IBD vs. IBS, P< 0,05 at cecum, rectum) (Table 2). Intensity of IL-1β was rather similar in IBS patients and controls.

4. IBS Subgroups

Intensity of TNF-α was lower in IBS-D patients throughout the epithelium and crypts of terminal ileum, cecum and rectum in comparison with IBS-C or IBS-A patients (Table 3). Intensity of TNF-α in IBS-A patients was higher at the rectum and terminal ileum crypts as well as at rectum epithelium (P> 0.05). No statistically significant differences were found in intensity of IL-6 at terminal ileum, cecum and rectum of IBS subgroups, except a significant raise in rectum crypts of IBS-D patients (IBS-D vs. IBS-C/IBS-A, P= 0.001) (Table 3). Finally, intensity of IL-1β was rather similar in all IBS subgroups without significant differences at the terminal ileum, cecum and rectum.

DISCUSSION

Investigation of pathogenesis in IBDs by analyzing the inflamed mucosa from patients with UC and CD has revealed the increased expression of certain proinflammatory cytokines such as IL-1, IL-6, IL-8, and TNF-α [9]. IL-6 is a pleiotropic cytokine that exerts certain proinflammatory effects and is associated with neoplasia and autoimmune disorders [10]. Stimulation of IL-6 results in a maximal induction of nuclear factor kB (NF-kB) activation and NF-kB nuclear translocation and induces expression of intercellular adhesion molecule 1, an adhesion molecule shown to be important in the neutrophil-epithelial interactions in IBD [11]. IL-6 plays a central role in several immunologic responses during the development of IBD, and circulating levels of IL-6 are associated with many clinical features of CD and UC [12].

IL-6 is expressed in a significantly higher amount in both serum and tissue of patients with active IBD and its levels have been correlated with the severity of the disease and are associated with the prediction of disease activity. T-cell accumulation, mediated by apoptosis resistance, eventually leads to chronic inflammation and can be inhibited by anti-IL-6 receptor antibodies [13,14]. Overall, several studies have highlighted the role of IL-6 in innate and adaptive immune responses and suggest that deregulation of these pathways can contribute to the progression of chronic disease [15].

TNF-α and IL-1β play important roles in the regulation of the immunity, the inflammatory response and the cell growth and death of normal and cancerous cells [16-18]. IL-1 seems to be substantive in the pathogenesis of IBD because of its immunological up-regulatory and proinflammatory activities. IL-1, primarily secreted by monocytes and macrophages, activates intestinal macrophages, neutrophils, fibroblasts, and smoothmuscle cells, inducing them to secrete prostaglandins, proteases, and other soluble mediators of inflammation, and chemotactic cytokines [19].

TNF-α expression in human macrophages was discovered in the colonic tissue and macrophages in both patients with CD and UC and serum levels of TNF-α correlate with clinical and laboratory indices of intestinal disease activity [12]. TNF-α is considered to play an essential role in the pathogenesis of mucosal inflammation in IBD as supported by human and animal studies: (1) in a clinical trial approximately two-thirds of CD patients responded to treatment with a single infusion of anti-TNF-α chimeric monoclonal antibody; (2) amelioration of inflammation following anti-TNF-α treatment in several animal models of intestinal inflammation is presented; (3) the development of a “Crohn’s-like” phenotype in mice that overexpress TNF-α has been shown [9]. TNF-α antibodies have a documented initial effect in 60% to 70% of patients with moderate to severe luminal and/or fistulizing IBD and approximately 30% of patients achieve remission after a relatively short treatment period [20]. Nevertheless, the effect seems to decrease during long-term treatment.

In our study intensity of TNF-α was shown decreased in IBD patients in comparison with IBS patients or controls. Several studies have demonstrated increased mucosal levels of TNF-α in IBD patients [21,22], whereas others were unable to detect increased levels of TNF-α [23,24]. Likewise, the mucosal levels of IL1β were decreased in IBD patients comparing to IBS patients or controls. On the contrary IL-6 mucosal levels were augmented in IBD patients comparing to the aforementioned groups, which corresponds with several studies that place IL-6 as a key factor in IBD [11,25].

Furthermore, it is beguiling that TNF-α mucosal levels were increased in IBS patients in comparison to IBD patients or controls, showing that TNF-α could participate in IBS pathogenesis. Probably, additional research of TNF-α serum levels in IBs patients would provide further data, considering the confirmed elevation in IBD patients, demonstrated in several studies [12]. Levels of IL-6 and IL-1β were similar with those detected in controls revealing possibly a nonsignificant role in IBS. Analyzing IBS subgroups based on symptomatology revealed subtle differences only regarding TNF-α, showing a decrease in IBS-D patients and an increase in IBS-C patients, and no differences in IL-6 and IL-1β in IBS subgroups.

Unprotected elevated levels of TNF-α, IL-6 and IL-1β in controls could be attributable to normal intestinal inflammation [26]. Normal bowel inflammation is a normal response that prevents bowel injury by its ability to fit perfectly into multiple proinflammatory challenges and is therefore essential to homeostasis. The intestine develops and functions within a complex and large microbial load and a steady stream of dietary antigens leading to a “normal inflammation” condition. Anti-inflammatory cytokines such as IL-10 could contribute to diminishing inflammatory procedures in normal controls.

In conclusion, our study demonstrated that IL-6 is probably the most important proinflammatory cytokine in IBD patients, whereas in IBS patients, TNF-α seems a more challenging factor in the disease pathogenesis. Further studies investigating anti-inflammatory or other proinflammatory cytokines in IBS, would provide additional information in the ambiguous pathophysiology mechanisms of IBS as well as the IL-17/Th17 (Thelper 17) axis which is assumed to play an important role in regulating intestinal tissue inflammation [27], and thus, contribute to more effective management.

NOTES

FINANCIAL SUPPORT

The authors received no financial support for the research, authorship, and/or publication of this article.

CONFLICT OF INTEREST

No potential conflict of interest relevant to this article was reported.

AUTHOR CONTRIBUTION

Conceptualization: Grammeniatis V. Methodology: Mitselou A, Grammeniatis V, Galani V. Formal analysis: Katsanos K. Project administration: all authors. Writing - original draft: Grammeniatis V, Varouktsi A, Papadatos SS. Writing - review & editing: Mitselou A, Galani V. Approval of final manuscript: all authors

Table 1.

Characteristics of IBD Patients, Controls and IBS Subgroups

Characteristic	IBS			IBD			Controls
Characteristic	IBS-D	IBS-C	IBS-A	Terminal ileum	Cecum	Rectum	Controls
Mean age (yr)	44	54	43	35	38	46	46
Range (yr)	19–61	23–66	40–52	17–61	24–48	21–60	18–72
Number	5	9	3	18	18	14	19

IBS subtypes: IBS-D, predominant symptom diarrhea; IBS-C, predominant symptom constipation; IBS-A, patients with alternating symptoms.

Table 2.

TNF-α, IL-6 and IL-1β in Terminal Ileum, Cecum and Rectum of IBS patients, IBD Patients and Controls

Bowel parts, cytokines	IBD		IBS		Controls
Bowel parts, cytokines	Epithelium intensity	Crypts intensity	Epithelium intensity	Crypts intensity	Epithelium intensity	Crypts intensity
Terminal ileum
TNF-α	1.00^a	0.68	2.38^b	2.00	1.94^b	1.61
IL-6	2.17^a	1.89^a	1.65^b	1.22^b	1.95^b	1.70^b
IL-1β	2.31^a	2.31^a	2.70^a,^b	2.95^a,^b	2.84^b	2.85^b
Cecum
TNF-α	0.80^a	0.80	2.90^b	2.35	2.38^c	2.00
IL-6	2.31^a	2.16^a	1.72^b	1.41^b	1.76^b	1.40^b
IL-1β	2.65^a	2.56^a	3.05^b	3.10^b	3.25^b	2.65^b
Rectum
TNF-α	1.17^a	1.17	2.55^b	2.30	2.63^b	2.15^b
IL-6	1.87^a	2.08^a	1.73^b	1.46^b	1.55^b	1.47^b
IL-1β	2.54^a	2.46^a	2.91^b	2.95^b	3.10^b	2.89^b

Statistically significant;

^a P<0.05.,

^b P<0.01, and

^c P<0.001.

IL, interleukin.

Table 3.

TNF-α, IL-6, IL-1β in Terminal Ileum, Cecum, and Rectum of IBS Subgroups

IBS subtypes	Terminal ileum		Cecum		Rectum
IBS subtypes	Epithelium intensity	Crypts intensity	Epithelium intensity	Crypts intensity	Epithelium intensity	Crypts intensity
TNF-α
IBS-D	2.00^a	2.00^a	2.67^a	2.00^a	2.60^a	2.20^a
IBS-C	2.33^a	1.77	3.22	2.77	2.55	2.44
IBS-A	2.33^a	2.67	3.00	3.00	3.00	2.67
IL-6
IBS-D	1.60^a	1.00^a	1.50^a	1.50^a	3.20^a	2.00^b
IBS-C	1.55^a	1.14^a	1.44^a	1.00^a	2.90^a	1.00^a
IBS-A	1.77^a	1.50^a	1.67^a	1.33^a	3.00^a	1.00^a
IL-1β
IBS-D	3.00^a	2.60^a	2.75^a	3.00^a	3.20^a	3.00^a
IBS-C	2.89^a	3.10^a	3.00^a	3.00^a	2.90^a	3.10^a
IBS-A	2.67^a	3.30^a	3.00^a	3.00^a	3.00^a	3.00^a

Statistically significant;

^a P<0.05.,

^b P<0.001.

IL, interleukin; IBS subtypes: IBS-D, predominant symptom diarrhea; IBS-C, predominant symptom constipation; IBS-A, patients with alternating symptoms.

REFERENCES

1. Chadwick VS, Chen W, Shu D, et al. Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology 2002;122:1778–1783.Article PubMed
2. Oberndorff-Klein Woolthuis AH, Brummer RJ, de Wit NJ, Muris JW, Stockbrügger RW. Irritable bowel syndrome in general practice: an overview. Scand J Gastroenterol Suppl 2004;(241): 17–22.PubMed
3. Drossman DA, Camilleri M, Mayer EA, Whitehead WE. AGA technical review on irritable bowel syndrome. Gastroenterology 2002;123:2108–2131.Article PubMed
4. Cayley WE Jr. Irritable bowel syndrome. BMJ 2005;330:632.Article PubMed PMC
5. Spiller RC. Irritable bowel syndrome. Br Med Bull 2005;72:15–29.Article PubMed
6. Ohman L, Simrén M. Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions. Nat Rev Gastroenterol Hepatol 2010;7:163–173.Article PubMed PDF
7. Akiho H, Ihara E, Nakamura K. Low-grade inflammation plays a pivotal role in gastrointestinal dysfunction in irritable bowel syndrome. World J Gastrointest Pathophysiol 2010;1:97–105.Article PubMed PMC
8. Travis SP, Schnell D, Krzeski P, et al. Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). Gut 2012;61:535–542.Article PubMed
9. Papadakis KA, Targan SR. Role of cytokines in the pathogenesis of inflammatory bowel disease. Annu Rev Med 2000;51:289–298.Article PubMed
10. Galani V, Constantopoulos S, Manda-Stachouli C, et al. Additional proteins in BAL fluid of Metsovites environmentally exposed to asbestos: more evidence of “protection” against neoplasia? Chest 2002;121:273–278.Article PubMed
11. Wang L, Walia B, Evans J, Gewirtz AT, Merlin D, Sitaraman SV. IL-6 induces NF-kappa B activation in the intestinal epithelia. J Immunol 2003;171:3194–3201.Article PubMed
12. Sanchez-Munoz F, Dominguez-Lopez A, Yamamoto-Furusho JK. Role of cytokines in inflammatory bowel disease. World J Gastroenterol 2008;14:4280–4288.Article PubMed PMC
13. Mudter J, Neurath MF. Apoptosis of T cells and the control of inflammatory bowel disease: therapeutic implications. Gut 2007;56:293–303.Article PubMed PMC
14. Kallen KJ. The role of transsignalling via the agonistic soluble IL-6 receptor in human diseases. Biochim Biophys Acta 2002;1592:323–343.Article PubMed
15. Rose-John S, Scheller J, Elson G, Jones SA. Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer. J Leukoc Biol 2006;80:227–236.Article PubMed
16. Kastamoulas M, Chondrogiannis G, Kanavaros P, et al. Cytokine effects on cell survival and death of A549 lung carcinoma cells. Cytokine 2013;61:816–825.Article PubMed
17. Chondrogiannis G, Kastamoulas M, Kanavaros P, et al. Cytokine effects on cell viability and death of prostate carcinoma cells. Biomed Res Int 2014;2014:536049.Article PubMed PMC PDF
18. Galani V, Kastamoulas M, Varouktsi A, Lampri E, Mitselou A, Arvanitis DL. IFNs-signaling effects on lung cancer: an up-todate pathways-specific review. Clin Exp Med 2017;17:281–289.Article PubMed PDF
19. Scaldaferri F, Correale C, Gasbarrini A, Danese S. Mucosal biomarkers in inflammatory bowel disease: key pathogenic players or disease predictors? World J Gastroenterol 2010;16:2616–2625.Article PubMed PMC
20. Martinsen TC, Herter R, Dybdahl JH, Waldum HL. Use of TNFalpha antibodies in treatment of inflammatory bowel disease. Tidsskr Nor Laegeforen 2010;130:273–277.Article PubMed
21. Maeda M, Watanabe N, Neda H, et al. Serum tumor necrosis factor activity in inflammatory bowel disease. Immunopharmacol Immunotoxicol 1992;14:451–461.Article PubMed
22. Andus T, Targan SR, Deem R, Toyoda H. Measurement of tumor necrosis factor alpha mRNA in small numbers of cells by quantitative polymerase chain reaction. Reg Immunol 1993;5:11–17.PubMed
23. Youngman KR, Simon PL, West GA, et al. Localization of intestinal interleukin 1 activity and protein and gene expression to lamina propria cells. Gastroenterology 1993;104:749–758.Article PubMed
24. Oliva-Hemker M, Fiocchi C. Etiopathogenesis of inflammatory bowel disease: the importance of the pediatric perspective. Inflamm Bowel Dis 2002;8:112–128.Article PubMed
25. Ruffolo C, Scarpa M, Faggian D, et al. Cytokine network in rectal mucosa in perianal Crohn’s disease: relations with inflammatory parameters and need for surgery. Inflamm Bowel Dis 2008;14:1406–1412.Article PubMed
26. Fiocchi C. What is “physiological” intestinal inflammation and how does it differ from “pathological” inflammation? Inflamm Bowel Dis 2008;14 Suppl 2:S77–S78.Article PubMed
27. Monteleone I, Pallone F, Monteleone G. Interleukin-23 and Th17 cells in the control of gut inflammation. Mediators Inflamm 2009;2009:297645.Article PubMed PMC PDF

Figure & Data

REFERENCES

Citations

Citations to this article as recorded by

The Role of Bacteria-Derived Hydrogen Sulfide in Multiple Axes of Disease
Aleksandr Birg, Henry C. Lin
International Journal of Molecular Sciences.2025; 26(7): 3340. CrossRef
Guardians at the Gate: Immune System in Gastrointestinal Diseases
Elena Layunta, Jose Emilio Mesonero, Eva Latorre
International Journal of Molecular Sciences.2024; 25(11): 5933. CrossRef
Novel Dairy Fermentates Have Differential Effects on Key Immune Responses Associated with Viral Immunity and Inflammation in Dendritic Cells
Dearbhla Finnegan, Claire Connolly, Monica A. Mechoud, Jamie A. FitzGerald, Tom Beresford, Harsh Mathur, Lorraine Brennan, Paul D. Cotter, Christine E. Loscher
Foods.2024; 13(15): 2392. CrossRef
The Latest Data Concerning the Etiology and Pathogenesis of Irritable Bowel Syndrome
Vlad Alexandru Ionescu, Gina Gheorghe, Teodor Florin Georgescu, Nicolae Bacalbasa, Florentina Gheorghe, Camelia Cristina Diaconu
Journal of Clinical Medicine.2024; 13(17): 5124. CrossRef
Morphological Changes of the Pituitary Gland in Patients with Irritable Bowel Syndrome Using Magnetic Resonance Imaging
Jessica Abou Chaaya, Jennifer Abou Chaaya, Batoul Jaafar, Lea Saab, Jad Abou Chaaya, Elie Al Ahmar, Elias Estephan
Journal of Imaging.2024; 10(9): 226. CrossRef
Review article: The role of the gut–brain axis in inflammatory bowel disease and its therapeutic implications
Christy Riggott, Alexander C. Ford, David J. Gracie
Alimentary Pharmacology & Therapeutics.2024; 60(9): 1200. CrossRef
Novel hypothesis and therapeutic interventions for irritable bowel syndrome: interplay between metal dyshomeostasis, gastrointestinal dysfunction, and neuropsychiatric symptoms
Yutaka Nakagawa, Shizuo Yamada
Molecular and Cellular Biochemistry.2024;[Epub] CrossRef
Unraveling the intricacies of neutrophil extracellular traps in inflammatory bowel disease: Pathways, biomarkers, and promising therapies
Yilin Wu, Jun Shen
Cytokine & Growth Factor Reviews.2024; 80: 156. CrossRef
Transcriptional Responses of Lacticaseibacillus rhamnosus to TNFα, IL-6, IL-8, and IL-10 Cytokines
Ksenia M. Klimina, Marina S. Dyachkova, Vladimir A. Veselovsky, Natalia V. Zakharevich, Aleksandra A. Strokach, Oksana V. Selezneva, Egor A. Shitikov, Dmitry A. Bespiatykh, Roman A. Yunes, Elena U. Poluektova, Maya V. Odorskaya, Polina S. Ostroukhova, Ser
Biology.2024; 13(11): 931. CrossRef
Exploring Gut Microbiota Imbalance in Irritable Bowel Syndrome: Potential Therapeutic Effects of Probiotics and Their Metabolites
María José García Mansilla, María Jesús Rodríguez Sojo, Andrea Roxana Lista, Ciskey Vanessa Ayala Mosqueda, Antonio Jesús Ruiz Malagón, Julio Gálvez, Alba Rodríguez Nogales, María José Rodríguez Sánchez
Nutrients.2024; 17(1): 155. CrossRef
Evaluation of two laboratory model methods for diarrheal irritable bowel syndrome
Qian Chen, Hua Zhang, Chang-Yue Sun, Qing-Ying He, Rui-Rong Zhang, Bin-Fei Luo, Zi-Hao Zhou, Xiao-Fan Chen
Molecular Medicine.2023;[Epub] CrossRef
Structural properties and anti-inflammatory activity of purified polysaccharides from Hen-of-the-woods mushrooms (Grifola frondosa)
Xiaoyi Liu, Shuai Chen, Huijuan Liu, Jiao Xie, K. M. Faridul Hasan, Qibing Zeng, Shaofeng Wei, Peng Luo
Frontiers in Nutrition.2023;[Epub] CrossRef
An Asian perspective on irritable bowel syndrome
Kee Wook Jung, Seung-Jae Myung
Intestinal Research.2023; 21(2): 189. CrossRef
Molecular Mechanisms of the Antitumor Effects of Mesalazine and Its Preventive Potential in Colorectal Cancer
Joanna Słoka, Marcel Madej, Barbara Strzalka-Mrozik
Molecules.2023; 28(13): 5081. CrossRef
Structure and Metabolic Activity of the Gut Microbiota in Diarrhea-Predominant Irritable Bowel Syndrome Combined with Functional Dyspepsia
Aleksandra Kovaleva, Elena Poluektova, Roman Maslennikov, Oxana Zolnikova, Oleg Shifrin, Anna Kudryavtseva, George Krasnov, Maria Fedorova, Anna Karchevskaya, Vladimir Ivashkin
Gastrointestinal Disorders.2023; 5(3): 296. CrossRef
NK cells vs. obesity: A tale of dysfunction & redemption
Conor De Barra, Donal O'Shea, Andrew E. Hogan
Clinical Immunology.2023; 255: 109744. CrossRef
Non-invasive neuromodulation: an emerging intervention for visceral pain in gastrointestinal disorders
Md Jahangir Alam, Jiande D. Z. Chen
Bioelectronic Medicine.2023;[Epub] CrossRef
Gut–Brain Axis, Microbiota and Probiotics—Current Knowledge on Their Role in Irritable Bowel Syndrome: A Review
Cristina Maria Marginean, Mihaela Popescu, Andrei Ioan Drocas, Sergiu Marian Cazacu, Radu Mitrut, Iulia Cristina Marginean, George Alexandru Iacob, Marian Sorin Popescu, Anca Oana Docea, Paul Mitrut
Gastrointestinal Disorders.2023; 5(4): 517. CrossRef
Comparative treatment of Sulfasalazine+Ezetimibe combination and Sulfasalazine in a rat model with induced colitis
Farrah Rasool Jaafar, Ahmed Abu-Raghif
Journal of Medicine and Life.2023; 16(8): 1165. CrossRef
Screening and Evaluation of Probiotics for Reducing Intestinal Inflammation
雅君陈
Hans Journal of Food and Nutrition Science.2022; 11(01): 44. CrossRef
Protection against ulcerative colitis and colorectal cancer by evodiamine via anti‑inflammatory effects
Yongfeng Zhang, Yaqin Zhang, Yang Zhao, Wanyue Wu, Weiqi Meng, Yulin Zhou, Ye Qiu, Chenliang Li
Molecular Medicine Reports.2022;[Epub] CrossRef
The Role of Neuro-Immune Interaction in Chronic Pain Conditions; Functional Somatic Syndrome, Neurogenic Inflammation, and Peripheral Neuropathy
Elaine Meade, Mary Garvey
International Journal of Molecular Sciences.2022; 23(15): 8574. CrossRef
Ameliorating effects of electroacupuncture on the low‐grade intestinal inflammation in rat model of diarrhea‐predominant irritable bowel syndrome
Xuemei Li, Kuiyu Ren, Xiaojuan Hong, Sha Guo, Shuguang Yu, Sha Yang
Journal of Gastroenterology and Hepatology.2022; 37(10): 1963. CrossRef
Healthy Sleep Every Day Keeps the Doctor Away
Cailan Lindsay Feingold, Abbas Smiley
International Journal of Environmental Research and Public Health.2022; 19(17): 10740. CrossRef
Compositional Changes in the Gut Microbiota of Responders and Non-responders to Probiotic Treatment Among Patients With Diarrhea-predominant Irritable Bowel Syndrome: A Post Hoc Analysis of a Randomized Clinical Trial
Seung Yong Shin, Sein Park, Jung Min Moon, Kisung Kim, Jeong Wook Kim, Jongsik Chun, Tae Hee Lee, Chang Hwan Choi
Journal of Neurogastroenterology and Motility.2022; 28(4): 642. CrossRef
Overlap of Functional Gastrointestinal Disorders: Common Mechanisms of Pathogenesis as a Key to Rational Therapy
S. N. Mekhdiyev, O. A. Mekhdieva, O. M. Berko
Russian Journal of Gastroenterology, Hepatology, Coloproctology.2022; 32(4): 95. CrossRef
Effect of Heat-Killed Lactobacillus casei DKGF7 on a Rat Model of Irritable Bowel Syndrome
Gyeol Seong, Seungbaek Lee, Yang Won Min, Yeon Sil Jang, Hong Seog Kim, Eui-Joong Kim, So-Young Park, Cheol-Hyun Kim, Dong Kyung Chang
Nutrients.2021; 13(2): 568. CrossRef
A Comprehensive Review: Sphingolipid Metabolism and Implications of Disruption in Sphingolipid Homeostasis
Brianna M. Quinville, Natalie M. Deschenes, Alex E. Ryckman, Jagdeep S. Walia
International Journal of Molecular Sciences.2021; 22(11): 5793. CrossRef
Lactiplantibacillus plantarum 299v (LP299V®): three decades of research
E. Arvidsson Nordström, C. Teixeira, C. Montelius, B. Jeppsson, N. Larsson
Beneficial Microbes.2021; 12(5): 441. CrossRef
Immunohistochemical Study of Adhesion Molecules in Irritable Bowel Syndrome
Antigony Mitselou, Vasileios Grammeniatis, Anna Varouktsi, Stamatis S. Papadatos, Antonios Klaroudas, Konstantinos Katsanos, Vasiliki Galani
Advanced Biomedical Research.2021; 10(1): 21. CrossRef
TNF-α, IL-17, and IL-22 production in the rectal mucosa of nonceliac wheat sensitivity patients: role of adaptive immunity
Pasquale Mansueto, Diana Di Liberto, Francesca Fayer, Maurizio Soresi, Girolamo Geraci, Antonio Giulio Giannone, Aurelio Seidita, Alberto D’Alcamo, Francesco La Blasca, Marianna Lo Pizzo, Ada Maria Florena, Francesco Dieli, Antonio Carroccio
American Journal of Physiology-Gastrointestinal and Liver Physiology.2020; 319(3): G281. CrossRef
Sudachinoid- and Ichangensin-Type Limonoids from Citrus junos Downregulate Pro-Inflammatory Cytokines
Jihun Shin, Hwa Young Song, Mina Lee
International Journal of Molecular Sciences.2020; 21(18): 6963. CrossRef
Differential clusterization of soluble and extracellular vesicle-associated cytokines in myocardial infarction
Anna Lebedeva, Wendy Fitzgerald, Ivan Molodtsov, Alexander Shpektor, Elena Vasilieva, Leonid Margolis
Scientific Reports.2020;[Epub] CrossRef
Lactoferrin in the Prevention and Treatment of Intestinal Inflammatory Pathologies Associated with Colorectal Cancer Development
Antimo Cutone, Giusi Ianiro, Maria Stefania Lepanto, Luigi Rosa, Piera Valenti, Maria Carmela Bonaccorsi di Patti, Giovanni Musci
Cancers.2020; 12(12): 3806. CrossRef

PubReader
ePub Link

Cite

CITE: export Copy Download Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

Proinflammatory cytokines in irritable bowel syndrome: a comparison with inflammatory bowel disease

Intest Res. 2020;18(1):115-120. Published online January 30, 2020

DOI: https://doi.org/10.5217/ir.2019.00125

XML Download

Related articles

Proinflammatory cytokines in irritable bowel syndrome: a comparison with inflammatory bowel disease

Characteristic	IBS			IBD			Controls
Characteristic	IBS-D	IBS-C	IBS-A	Terminal ileum	Cecum	Rectum	Controls
Mean age (yr)	44	54	43	35	38	46	46
Range (yr)	19–61	23–66	40–52	17–61	24–48	21–60	18–72
Number	5	9	3	18	18	14	19

Bowel parts, cytokines	IBD		IBS		Controls
Bowel parts, cytokines	Epithelium intensity	Crypts intensity	Epithelium intensity	Crypts intensity	Epithelium intensity	Crypts intensity
Terminal ileum
TNF-α	1.00^a	0.68	2.38^b	2.00	1.94^b	1.61
IL-6	2.17^a	1.89^a	1.65^b	1.22^b	1.95^b	1.70^b
IL-1β	2.31^a	2.31^a	2.70^a,^b	2.95^a,^b	2.84^b	2.85^b
Cecum
TNF-α	0.80^a	0.80	2.90^b	2.35	2.38^c	2.00
IL-6	2.31^a	2.16^a	1.72^b	1.41^b	1.76^b	1.40^b
IL-1β	2.65^a	2.56^a	3.05^b	3.10^b	3.25^b	2.65^b
Rectum
TNF-α	1.17^a	1.17	2.55^b	2.30	2.63^b	2.15^b
IL-6	1.87^a	2.08^a	1.73^b	1.46^b	1.55^b	1.47^b
IL-1β	2.54^a	2.46^a	2.91^b	2.95^b	3.10^b	2.89^b

IBS subtypes	Terminal ileum		Cecum		Rectum
IBS subtypes	Epithelium intensity	Crypts intensity	Epithelium intensity	Crypts intensity	Epithelium intensity	Crypts intensity
TNF-α
IBS-D	2.00^a	2.00^a	2.67^a	2.00^a	2.60^a	2.20^a
IBS-C	2.33^a	1.77	3.22	2.77	2.55	2.44
IBS-A	2.33^a	2.67	3.00	3.00	3.00	2.67
IL-6
IBS-D	1.60^a	1.00^a	1.50^a	1.50^a	3.20^a	2.00^b
IBS-C	1.55^a	1.14^a	1.44^a	1.00^a	2.90^a	1.00^a
IBS-A	1.77^a	1.50^a	1.67^a	1.33^a	3.00^a	1.00^a
IL-1β
IBS-D	3.00^a	2.60^a	2.75^a	3.00^a	3.20^a	3.00^a
IBS-C	2.89^a	3.10^a	3.00^a	3.00^a	2.90^a	3.10^a
IBS-A	2.67^a	3.30^a	3.00^a	3.00^a	3.00^a	3.00^a

Table 1. Characteristics of IBD Patients, Controls and IBS Subgroups

IBS subtypes: IBS-D, predominant symptom diarrhea; IBS-C, predominant symptom constipation; IBS-A, patients with alternating symptoms.

Table 2. TNF-α, IL-6 and IL-1β in Terminal Ileum, Cecum and Rectum of IBS patients, IBD Patients and Controls

Statistically significant;

P<0.05.,

P<0.01, and

P<0.001.

IL, interleukin.

Table 3. TNF-α, IL-6, IL-1β in Terminal Ileum, Cecum, and Rectum of IBS Subgroups

Statistically significant;

P<0.05.,

P<0.001.

IL, interleukin; IBS subtypes: IBS-D, predominant symptom diarrhea; IBS-C, predominant symptom constipation; IBS-A, patients with alternating symptoms.